Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer
Alessandra Fabi(Agostino Gemelli University Polyclinic), Marcella Mottolese, Stefania Gori(Ospedale Sacro Cuore Don Calabria), Mirella Marino, Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Mariangela Ciccarese(Ospedale Vito Fazzi), Francesco Cognetti(Apple (Israel)), Paola Malaguti, Roberta Merola, Barbara Antoniani, G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Isabella Sperduti(San Gallicano Hospital), Cristiana Ercolani, Anna Di Benedetto, Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico), Paola Papaldo(Cancer Institute (WIA)), Claudio Botti(Catholic University of America)
Cited by 17
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
The Integrated Genomic Landscape of Thymic Epithelial Tumors
|Cancer Cell|2018|389
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
|Journal of Clinical Oncology|2020|226